Table 2 The characteristics and clinical variables of patients in the prospective validation cohort
Clinical variable | Validation sepsis | P value | |
|---|---|---|---|
Sepsis survivors | Sepsis nonsurvivors | ||
No. | 134 | 54 | Â |
Age (years) | 61.8 ± 18.5 | 67 ± 14.4 | 0.07 |
Gender (male %) | 64.20% | 61.10% | 0.69 |
SOFA (median and IQR) | 7 (5–12) | 8 (6–13) | 0.22 |
APACHE II (median and IQR) | 18 (13–24) | 22 (18–30) | 0.001 |
MAP (mmHg) | 75.2 ± 14.9 | 65.8 ± 15.2 | 0.001 |
PCT (median and IQR) | 2.13 (0.26–15.9) | 2.53 (0.74–36.5) | 0.086 |
Pathogen | |||
S. aureus [N (%)] | 13 (9.7%) | 4 (7.4%) | 0.62 |
K. pneumoniae [N (%)] | 23 (17.2%) | 4 (7.4%) | 0.084 |
E. coli [N (%)] | 9 (6.7%) | 4 (7.4%) | 0.86 |
Source of infection | |||
 Respiratory [N (%)] | 46 (34.3%) | 23 (42.6%) | 0.29 |
 Abdominal [N (%)] | 18 (13.4%) | 7 (13.0%) | 0.94 |
 Urinary tract [N (%)] | 6 (4.5%) | 3 (5.6%) | 0.75 |
 Blood [N (%)] | 33 (24.6%) | 8 (14.8%) | 0.14 |
 Others [N (%)] | 31 (23.1%) | 13 (24.1%) | 0.88 |
Comorbidities | |||
 Diabetes mellitus [N (%)] | 32 (23.9%) | 16 (29.6%) | 0.42 |
 Cardiovascular disease [N (%)] | 43 (32.1%) | 23 (42.6%) | 0.17 |
 Malignancy [N (%)] | 16 (11.9%) | 11 (20.4%) | 0.13 |
 COPD [N (%)] | 5 (3.7%) | 2 (3.7%) | 1 |
 Chronic kidney disease [N (%)] | 8 (6.0%) | 2 (3.7%) | 0.53 |
 Chronic liver disease [N (%)] | 8 (6.0%) | 1 (1.9%) | 0.24 |
 Nervous system disease [N (%)] | 20 (14.9%) | 14 (25.9%) | 0.077 |
 Immunosuppression [N (%)] | 14 (10.4%) | 8 (14.8%) | 0.4 |